864237-02-5

Basic information

• Product Name: methyl 7-hydroxyisoquinoline-3-carboxylate
• Synonyms: methyl 7-hydroxyisoquinoline-3-carboxylate
• CAS NO: 864237-02-5
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19406
• Mol File: 864237-02-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 7-hydroxyisoquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 7-hydroxyisoquinoline-3-carboxylate(864237-02-5)
• EPA Substance Registry System: methyl 7-hydroxyisoquinoline-3-carboxylate(864237-02-5)

Safety Data

• Hazardous Substances Data: 864237-02-5(Hazardous Substances Data)

Upstream product

• 765952-41-8 methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 

Downstream Products

• 864236-90-8 C₂₁H₁₈F₄N₄O₂ 
• 1020568-45-9 7-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-3-isoquinolinecarboxylic acid 
• 1020568-69-7 methyl 7-[4-({[3-(2-chlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-3-isoquinolinecarboxylate 
• 1020568-64-2 methyl 7-(4-hydroxyphenyl)-3-isoquinolinecarboxylate 

Relevant articles and documents

Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors

RAF kinase plays a critical role in the RAF-MEK-ERK signaling pathway and inhibitors of RAF could be of use for the treatment of various cancer types. We have designed potent RAF-1 inhibitors bearing novel bicyclic heterocycles as key structural elements for the interaction with the hinge region. In both series exploration of the SAR was focussed on the substitution of the phenyl ring, which binds to the induced fit pocket. Overall, it was confirmed that incorporation of lipophilic substituents was needed for potent Raf inhibition and a number of potent analogues were obtained.

ISOQUINOLINE DERIVATIVES

The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.